Protein purification and viral inactivation

Abstract

The present invention provides a method for purifying a target protein from a cell culture sample, the method comprising an affinity chromatography step, a viral inactivation step, and optionally other purification steps, wherein the cell culture sample contains the target protein, viral compounds, and other product- and process-related impurities, wherein the affinity chromatography step comprises: a) loading an affinity chromatography column with the cell culture sample, thereby binding the target protein to the affinity chromatography column; b) eluting the target protein from the affinity chromatography column by contacting the affinity chromatography column with an elution buffer having a pH<6 and comprising an excipient, wherein the excipient is selected from the group consisting of disaccharides, polyols, and poly(ethylene glycol) polymers; c) collecting one or more fractions containing the target protein obtained from step (b); d) optionally combining the fractions obtained from step (c) to form an elution product pool; and wherein the viral inactivation step comprises: e) incubating the elution product pool at a pH of 2.5 to 4.5.

Description

[Technical Field]

[0001] Technical Field The present invention relates to an improved method for purifying a target protein from a cell culture sample, comprising an affinity chromatography step, a viral inactivation step and optionally other purification steps, wherein the cell culture sample contains the target protein, viral compounds and other product and process related impurities. [Background technology]

[0002] technical level Therapeutic applications of proteins, and especially monoclonal antibodies (mAbs), play an increasingly important role in today's medical needs. Key aspects in the downstream processing of biotechnologically produced proteins are the purity and process yield of the target protein. Therefore, downstream processes must be designed to ensure that the final product, which ultimately becomes the therapeutic agent administered to patients, exhibits low levels of product- and process-related impurities (e.g., high-molecular-weight aggregates) as well as process-related contaminants (e.g., host cell protein levels, DNA, endotoxins, leached protein A, and some cell culture medium additives). In addition, the process must be able to remove and inactivate viruses to ensure product safety.

[0003] Protein purification, and particularly mAb purification, is a complex and costly multistep process that typically involves Protein A affinity chromatography. Protein A affinity chromatography is a highly selective mAb purification step starting from complex cell culture media, typically resulting in mAb purity of greater than 95%. When a sample solution containing mAb is passed through a Protein A column, impurities such as media proteins, host cell proteins, nucleic acids, and endotoxins are removed in the flow-through, while the mAb product is retained within the column. The mAb product is eluted from the Protein A resin by lowering the pH using an acidic elution buffer, which reduces the interaction between the mAb and Protein A. The acidic conditions following the elution step are also favorable for inactivating pH-sensitive viral contaminants (Yoo, S.M., Ghosh, R. 2012. Simultaneous removal of leached protein A and aggregates from monoclonal antibodies using hydrophobic interaction membrane chromatography. Journal of Membrane Science, 390: 263-269). Therefore, since Protein A columns are eluted with low pH buffers, after elution the mAb product from Protein A chromatography is typically subjected to viral inactivation by incubation at low pH.

[0004] A limitation of Protein A chromatography and viral inactivation is that the elution of proteins or antibodies from the Protein A resin and the viral inactivation step must be performed under acidic conditions. Low pH treatment has been shown to successfully inactivate retroviruses in various biotechnology products (Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., Xu, Y. 2003. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins, Biotechnology and Bioengineering 82, 321-329). However, exposure to low pH conditions can result in the formation of soluble high-molecular-weight aggregates and / or insoluble precipitates during product elution. The formation of high-molecular-weight aggregates can lead to reduced product yields if significant levels of product species aggregate.

[0005] Strategies to address protein aggregation during Protein A chromatography have been described by adding excipients, such as arginine and urea, as protein stabilizers at low pH during Protein A chromatography. The addition of urea at concentrations of 0.5 M and 1 M, respectively, was effective in reducing aggregation on the column and in solution (Shukla, AA, Hubbard, B., Tressel, T., Guhan, S., Low, D. 2007. Downstream processing of monoclonal antibodies—application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848(1):28-39). Protein A chromatography using an arginine solution as the eluent was found to prevent protein aggregation during elution from Protein A (Arakawa, T., Philo, JS, Tsumoto, K., Yumioka, R., Ejima, D. 2004. Elution of antibodies from a protein-A column by aqueous arginine solutions, Protein Expr. Purif. 36, 244-248).

[0006] There remains a need in the biopharmaceutical industry to define improved methods to reduce the risk of protein aggregation during low pH steps in downstream processing. In particular, the approach of adding pharmaceutically acceptable stabilizing excipients to the elution buffer of Protein A affinity chromatography has attracted great interest, as this buffer system also plays an important role in the following critical processing step, viral inactivation. Summary of the Invention

[0007] SUMMARY OF THE INVENTION Surprisingly, we have found that in the purification processing of biopharmaceutical proteins such as mAbs, the addition of a neutral excipient selected from the group consisting of disaccharides, polyols, and poly(ethylene glycol) polymers to the elution buffer of Protein A affinity chromatography prevents aggregation and precipitation of the target protein, resulting in increased product yields from the eluted product pool. Furthermore, we have found that the selected excipient effectively stabilizes the mAb during low-pH treatment in the viral inactivation step and does not interfere with viral inactivation during low-pH treatment. Because the selected excipient is acceptable and useful in pharmaceutical preparations containing the target mAb, there is no need to remove the excipient in further processing steps.

[0008] In particular, the present invention relates to a method for purifying a target protein from a cell culture sample, comprising an affinity chromatography step, a viral inactivation step and optionally other purification steps, wherein the cell culture sample contains the target protein, viral compounds, and other product and process related impurities, and wherein the affinity chromatography step comprises: a) loading an affinity chromatography column with a cell culture sample, thereby binding the target protein to the affinity chromatography column; b) eluting the target protein from the affinity chromatography column by contacting the affinity chromatography column with an elution buffer having a pH<6 and containing an excipient, wherein the excipient is selected from the group consisting of a disaccharide, a polyol, and a poly(ethylene glycol) polymer; c) collecting one or more fractions containing the target protein obtained from step (b); d) combining the fractions obtained from step (c) to form an elution product pool; and wherein the viral inactivation step comprises: e) incubating the elution product pool at a pH of 2-5; The method includes:

[0009] According to a preferred embodiment of the present invention, the affinity chromatography step is a Protein A affinity chromatography step. According to another preferred embodiment of the present invention, the target protein is a monoclonal antibody. According to another preferred embodiment of the present invention, the poly(ethylene glycol) polymer has an average molecular weight of 1,000 g / mol to 10,000 g / mol. According to an advantageous aspect of the invention, the excipient is selected from the group consisting of sucrose, trehalose, sorbitol, mannitol and PEG4000.

[0010] In a preferred embodiment of the present invention, the elution buffer has an excipient concentration of 2% to 15% by weight, even more preferably 5% to 10% by weight. In another preferred embodiment of the present invention, the elution buffer is a citrate buffer. Preferably, the elution buffer has a pH of 2.5 to 5.5.

[0011] According to a further advantageous aspect of the invention, the elution step (b) comprises contacting the affinity chromatography column with an elution buffer using an elution buffer gradient from pH 5.5 to pH 2.75. According to another advantageous aspect of the invention, prior to incubation step (e), the pH of the elution product pool is adjusted to a pH in the range of pH 2 to pH 5. According to another advantageous embodiment of the invention, the incubation step (e) is carried out at a pH between 2.5 and 4.5. According to another preferred embodiment of the present invention, the incubation step (e) is carried out at room temperature.

[0012] Detailed Description of the Invention In optimizing the downstream processing of biopharmaceutical proteins, the focus is on achieving high product yield and high product purity. However, many biopharmaceutical active proteins, and monoclonal antibodies in particular, tend to form and precipitate dimers, oligomers, or higher-order aggregates during processing steps performed at low pH conditions, such as affinity chromatography and viral inactivation steps. To provide therapeutic protein products with the required purity, these aggregated protein species must be removed during the purification process. The present invention now provides a method for purifying a target protein from a cell culture sample, comprising an affinity chromatography step, a viral inactivation step, and optionally other purification steps, wherein the cell culture sample contains the target protein, viral compounds, and other product- and process-related impurities, and wherein the affinity chromatography step comprises elution of the target protein with an elution buffer having a pH <6 and comprising an excipient selected from the group consisting of disaccharides, polyols, and poly(ethylene glycol) polymers.

[0013] It was found that adding selected excipients to one of the elution buffers can stabilize target proteins in low pH solutions, which is reflected in low protein aggregation and high target protein yield. Surprisingly, it was found that the selected excipients do not interfere with the subsequent viral inactivation step, which is also performed under low pH conditions. Rather, it was also found that the selected excipients stabilize the target protein during the low pH incubation period. Because the selected excipients are pharmaceutically acceptable and can be safely administered to humans and animals, there is no need to remove them from the purification process. This allows downstream processing of biopharmaceutical proteins to be optimized for lower costs and reduced processing times.

[0014] The term "affinity chromatography" refers to a chromatographic process that separates biochemical mixtures based on highly specific interactions, such as antigens and antibodies, enzymes and substrates, receptors and ligands, or proteins and nucleic acids. Examples of such chromatography resins include, but are not limited to, Protein A resin, Protein G resin, Protein L resin, immobilized metal ion affinity chromatography, etc. In a specific embodiment of the invention, the affinity chromatography column is a Protein A affinity chromatography column.

[0015] The term "Protein A affinity chromatography" refers to the separation or purification of substances and / or particles using Protein A, which is typically immobilized on a solid phase. Protein A is a 40-60 kD cell wall protein first discovered in Staphylococcus aureus. Binding of antibodies to Protein A resins is highly specific. Protein A affinity chromatography columns for use in Protein A affinity chromatography herein include, but are not limited to, Protein A immobilized on a polyvinyl ether solid phase, e.g., Eshmuno® columns (Merck, Darmstadt, Germany), Protein A immobilized on a pore glass matrix, e.g., ProSep® columns (Merck, Darmstadt, Germany), and Protein A immobilized on an agarose solid phase, e.g., MABSELECT TM SuRe TM column (GE Healthcare, Uppsala, Sweden).

[0016] The present invention may include further purification steps commonly applied in the purification process of target proteins from cell culture, non-limiting examples being column chromatography steps such as affinity chromatography columns, hydrophobic interaction columns and ion exchange columns, and filtration steps such as ultrafiltration and diafiltration.

[0017] The term "cell culture sample" refers to a sample derived from cell culture medium, i.e., a solution used during the cultivation, growth, or maintenance of cells, particularly mammalian host cells, and containing a target protein of interest. As used herein, a cell culture sample containing a target protein may be a harvested cell culture fluid sample or may be an eluate from a preceding filtration and / or chromatography step.

[0018] "Protein" includes macromolecules comprising one or more polypeptide chains, or at least one polypeptide chain of more than 100 amino acid residues. Polypeptides may also contain non-peptide components, such as carbohydrate groups. Carbohydrate groups and other non-peptide substituents may be added to polypeptides by the cell in which the polypeptide is produced and vary depending on the type of cell. Polypeptides are defined herein in terms of their amino acid backbone structure; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

[0019] As used herein, the term "antibody" refers to any form of antibody or fragment thereof, a protein that exhibits the desired biological activity. It is thus used broadly and specifically encompasses monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity. An "isolated antibody" refers to the purified state of the binding compound, meaning in this context that the molecule is substantially free of other biological molecules, such as nucleic acids, proteins, lipids, carbohydrates, or other materials, such as cell debris and growth medium. In general, the term "isolated" is not intended to refer to the complete absence of such materials or the absence of water, buffers, or salts, unless they are present in amounts that would substantially interfere with the experimental or therapeutic use of the binding compounds described herein.

[0020] As used herein, the term "monoclonal antibody" or "mAb" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically contain a large number of antibodies directed against (or specific for) different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention may be produced by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or may be produced by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using, for example, the techniques described in Clackson et al., (1991) Nature 352: 624-628 and Marks et al., (1991) J. Mol. Biol. 222: 581-597.

[0021] The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, so long as they exhibit the desired biological activity, as well as fragments of such antibodies (U.S. Pat. No. 4,816,567; and Morrison et al., (1984) Proc. Natl. Acad. Sci. USA 81: 6851-6855).

[0022] To recover the target protein or antibody in monomeric form from the affinity chromatography column, the adsorbed monomeric form of the protein is eluted from the affinity chromatography resin following adsorption. Elution of the adsorbed protein can be effected by applying an elution buffer that changes the pH conditions of the mobile phase in the column compared to the previous adsorption step.

[0023] The term "mobile phase" refers to any mixture of water and / or aqueous buffer and / or organic solvent that is suitable for recovering a polypeptide from a chromatography column. The terms "to elute" or "eluting" in this context are used as known to those skilled in the art and refer to the dissolution, and optionally the displacement, of adsorbed substance(s) from a fluid-impregnated solid or adsorbent, i.e., the column material to which the substance(s) are adsorbed.

[0024] As used herein, the term "buffer" refers to a buffer solution that resists changes in pH due to the action of its acid-base conjugate components. An "elution buffer" is a buffer used to elute proteins from a chromatography column. Elution buffers for the affinity chromatography step of the present invention typically have a pH <6. Those skilled in the art will recognize that the choice of pH will largely depend on the stability profile of the target protein of interest. In preferred embodiments, the pH is in the range of 2.5 to 5.5. Examples of buffers that control the pH within this range include phosphate, acetate, citrate, or ammonium buffers, or combinations thereof. A preferred such buffer is citrate.

[0025] In the present invention, the elution buffer comprises an excipient selected from the group consisting of disaccharides, polyols and poly(ethylene glycol). In an embodiment of the present invention, the excipient is a pharmaceutically acceptable compound. The term "pharmaceutically acceptable compound" refers to a compound that is non-toxic at the dosages and concentrations employed in the patent, and that is compatible with the other ingredients of the pharmaceutical formulation. In one embodiment, the excipient is a disaccharide. In a further embodiment, the disaccharide is sucrose or trehalose.

[0026] In another embodiment, the excipient is a polyol. In a preferred embodiment, the polyol is a sugar alcohol having at least four hydroxyl groups. Thus, in one embodiment, the polyol is selected from tetrol having four free hydroxyl groups, pentaol having five free hydroxyl groups, or hexaol having six free hydroxyl groups. In a preferred embodiment, the polyol is sorbitol or mannitol.

[0027] In one embodiment of the invention, the excipient is a poly(ethylene glycol) polymer. Although poly(ethylene glycol) polymers vary substantially in molecular weight, polymers having a molecular weight ranging from about 400 g / mol to about 30,000 g / mol are often suitable. In a preferred embodiment of the invention, polyethylene glycols having an average molecular weight ranging from 1,000 g / mol to 10,000 g / mol, more preferably from 3,000 g / mol to 5,000 g / mol, are suitably selected. In the present example, polyethylene glycol (PEG 4000) with an average molecular weight of 4,000 g / mol was selected.

[0028] In a preferred embodiment, the elution buffer has an excipient concentration of 2% to 15% by weight, and even more preferably 5% to 10% by weight. Any excipient may be used at a concentration higher than that required to achieve the intended stabilizing effect. Those skilled in the art can determine the effective and tolerable excipient concentration range for the methods described herein.

[0029] In one embodiment, one or more excipients may be present in the elution buffer that is applied to the chromatography material to elute target protein, particularly antibody.In one embodiment, the elution buffer comprises up to five different excipients.If more than one excipient is present in the solution, the total concentration of all excipients present in the solution is preferably within the range as defined above.For any single excipient or any combination of excipients, those skilled in the art will consider their individual solubility when determining the suitable concentration in the elution buffer. In a preferred embodiment according to the process of the present invention, the bind and elute chromatography step is followed by viral inactivation.

[0030] Preferably, the output or eluate from the bind and elute chromatography (affinity chromatography step) is subjected to viral inactivation, which renders the virus inactive or non-infectious, which is particularly important when the target molecule is intended for therapeutic use. Many viruses contain lipid or protein coats that can be inactivated by chemical changes. Some virus inactivation processes can completely denature the virus rather than simply inactivating it. Methods for inactivating viruses are well known to those skilled in the art. Some of the more widely used virus inactivation processes include, for example, the use of one or more of the following: solvent / detergent inactivation (e.g., with Triton X 100); pasteurization (heat); acidic pH inactivation; and ultraviolet (UV) inactivation. Two or more of these processes can be combined; for example, acidic pH inactivation can be performed at high temperatures.

[0031] To ensure complete and effective viral inactivation, viral inactivation is often performed over an extended period of time with constant agitation to ensure proper mixing of the viral inactivation agent with the sample. For example, in many processes used in industry today, the output or eluate from the capture step is collected in a pool tank and subjected to viral inactivation over an extended period of time (e.g., >1-2 hours, often followed by overnight storage). In various embodiments described herein, the time required for viral inactivation can be significantly reduced by performing the viral inactivation in-line or by employing a surge tank instead of a pool tank for this step. Examples of viral inactivation techniques that can be used in the processes described herein can be found, for example, in US2017320909(A1), which is incorporated herein by reference.

[0032] In a preferred embodiment of the present invention, viral inactivation employs the use of an acidic pH, where the output from the bind-and-elute chromatography step is subjected to acidic pH exposure for viral inactivation using either a surge tank or in-line. The pH used for viral inactivation is typically less than 5.0, or preferably 3.0-4.0. In some embodiments, the pH is about 3.6 or less. The time period used for viral inactivation using in-line methods can be 10 minutes or less, 5 minutes or less, 3 minutes or less, 2 minutes or less, or about 1 minute or less. For surge tank inactivation, the time required for inactivation is typically less than 1 hour, or preferably less than 30 minutes.

[0033] In some embodiments of the invention described herein, a suitable viral inactivation agent is introduced in-line between a chromatography process step and the next unit operation in the process (e.g., flow-through purification). Preferably, the tubing or connecting line contains a static mixer that ensures that the output from the chromatography process step is properly mixed with the viral inactivation agent before the output proceeds to the next unit operation. Typically, the output from bind-and-elute chromatography passes through the tubing at a flow rate that ensures minimal contact time with the viral inactivation agent. Contact time can be adjusted by using tubing of a certain length and / or diameter.

[0034] In some embodiments, a base or suitable buffer is additionally introduced into the tubing or connecting line after a period of exposure to the acid, thereby bringing the pH of the sample to a suitable pH for the next step, a pH that is not detrimental to the target molecule. Consequently, in preferred embodiments, both the exposure to low pH and the exposure to basic buffer are achieved in-line, including mixing via a static mixer.

[0035] In some embodiments, instead of or in addition to an in-line static mixer, a surge tank is used to treat the output from the bind and elute chromatography step with a viral inactivation agent, where the volume of the surge tank is no more than 25% of the total volume of the output from the bind and elute chromatography step, or no more than 15% or no more than 10% of the volume of the output from the bind and elute chromatography step, because more efficient mixing of the sample with the viral inactivation agent can be achieved when the volume of the surge tank is significantly less than the volume of a typical pool tank.

[0036] In some embodiments, viral inactivation can be achieved by altering the pH of the elution buffer in the bind and elute chromatography step, rather than having to add acid to the output from the affinity chromatography step. Typically, following viral inactivation, the sample is subjected to a flow-through purification process.

[0037] In some embodiments, a filtration step can be included after viral inactivation and before flow-through purification. Such a step can be desirable following viral inactivation (i.e., after adding both acid and base), particularly if sample turbidity is observed. In some embodiments, the filtration step can include a microporous filter or a depth filter. As described above, it has been found that the purified protein can be stabilized by adding a suitable excipient, and turbidity and undesired aggregation can be avoided. Thus, in a preferred embodiment of the present invention, both the virus inactivation step and the affinity chromatography step are carried out in the presence of at least an excipient selected from the group consisting of disaccharides, polyols, and poly(ethylene glycol) polymers. In a more preferred embodiment, the added excipient is selected from the group consisting of sucrose, trehalose, sorbitol, mannitol, and PEG4000. In this manner, the desired protein can be obtained in a purified and stabilized form while maintaining viral inactivation.

[0038] In the present invention, the elution product pool obtained from the affinity chromatography step is subjected to pH viral inactivation. Exposure to an acidic pH reduces or completely eliminates pH-sensitive viral contaminants. The pH viral inactivation step involves incubating the elution product pool for a period of time at a pH of 2 to 5, preferably 2.5 to 4.5, and particularly preferably 2.8 to 3.6. Typically, the pH viral inactivation step is completed by neutralizing the pH and, if necessary, removing particles by filtration.

[0039] In another embodiment of the present invention, the pH of the elution product pool can be adjusted to the pH desired for the viral inactivation step. In one embodiment, the pH of the elution product pool must be lowered by adding an acid, including, but not limited to, citric acid, acetic acid, caprylic acid, or other suitable acid. The pH level selected depends on the stability profile of the target protein component. In accordance with the present invention, the applied excipients present in the elution product pool can enhance the stability of the target protein during low-pH viral inactivation.

[0040] The stability of the target protein during low-pH viral inactivation is also affected by the duration of the low-pH incubation, which in one embodiment is 30 to 120 minutes, preferably 30 to 60 minutes. In another embodiment, viral inactivation is carried out at room temperature. [Brief explanation of the drawings]

[0041] Brief description of the drawings: [Figure 1]Figure 1 shows the stabilizing effect of certain excipients on mAbA during low pH treatment. The upper curve containing triangular markers shows the stabilizing effect of an exemplary neutral excipient (0.5 M sorbitol) on mAbA during low pH treatment, as indicated by stable or increasing mAbA monomer content over incubation time at pH 2.8 as measured by kinetic SEC. In comparison to the negative control, the lower curve containing circular markers shows the destabilizing effect of an exemplary ionic excipient (0.5 M arginine HCl) at low pH conditions, as indicated by a significant decrease in mAbA monomer content over incubation time at pH 2.8 (Example 1).

[0042] [Figure 2] Figure 2 is a bar graph showing the effect of certain excipients (sorbitol and arginine HCl) during low pH treatment as measured by nanoDSF (Example 1.5). Higher Tm values ​​than the "no additive control" (e.g., 0.5 M sorbitol) indicate stabilizing properties. A destabilizing effect was observed with the addition of arginine HCl. [Figure 3] Figure 3 is a bar graph showing the summarized effects of selected excipients (sorbitol, mannitol, sucrose, trehalose, PEG4000, and arginine HCl) on mAbA stability during low-pH treatment. Based on the kinetic SE-HPLC and nanoDSF results, selected neutral excipients (sorbitol, mannitol, sucrose, trehalose, and PEG4000) exhibited stabilizing effects during stress conditions, as indicated by positive delta values. However, PEG4000 could stabilize mAbA only in a citrate buffer system without added NaCl (Example 1).

[0043] [Figure 4]Figure 4 is a bar graph showing the summarized effect of selected excipients (sorbitol, mannitol, sucrose, trehalose, PEG4000, and arginine HCl) on mAbB stability during low-pH treatment. Based on the results of kinetic SE-HPLC and nanoDSF, selected neutral excipients (sorbitol, mannitol, sucrose, trehalose, and PEG4000) exhibited a stabilizing effect during stress conditions, as indicated by a decrease in monomer and an increase in Tm values. However, PEG4000 could stabilize mAbB only in a citrate buffer system without added NaCl (Example 1).

[0044] [Figure 5] Figure 5 is a bar graph showing the improved stability of mAbA caused by selected neutral excipients (sucrose, mannitol, trehalose, and PEG4000 and sorbitol) during low-pH viral inactivation at pH 2.8 for 60 minutes (Example 4).

[0045] [Figure 6] Figure 6 is a bar graph showing the improved stability of mAbB caused by selected neutral excipients (sucrose, mannitol, trehalose, and PEG4000 and sorbitol) during low pH viral inactivation at pH 2.8 for 60 minutes (Example 4).

[0046] [Figure 7] FIG. 7 is a flow diagram showing the process steps for low pH treatment at pH 3.6 using MLV virus (Example 5).

[0047] [Figure 8] FIG. 8 shows the viral reduction factors of MLV in the presence of selected neutral excipients (sorbitol, mannitol, sucrose, trehalose, and PEG4000) versus incubation time during low pH treatment (Example 6).

[0048] [Figure 9] FIG. 9 is a bar graph showing the viral reduction factors of MLV viruses in the presence of selected neutral excipients (sorbitol, mannitol, sucrose, trehalose and PEG4000) after 60 minutes of low pH treatment (Example 6). [Example]

[0049] example: Example 1: Stabilizing effect of selected excipients in low pH-induced aggregation tests (in-vitro) The effect of using neutral excipients on mAbs under low-pH stress conditions, mimicking Protein A chromatography and viral inactivation steps during downstream processing of monoclonal antibodies, was evaluated in vitro. In vitro screening studies were performed by incubation experiments of two model proteins (mAbA and mAbB) at low pH values ​​with or without added NaCl. The effects of these experiments on the conformational stability, fragmentation, and aggregation behavior of the samples were analyzed using kinetic-SEC and nanoDSF and compared to control conditions without excipients.

[0050] Furthermore, an ionic excipient (arginine HCl) was also used as a negative control to demonstrate the destabilizing effect of excipients that are not suitable for incubation in low pH conditions.

[0051] Example 1.1: Preparation of 0.25 M citrate buffer pH 3.0 Solution A: 0.25 M citric acid monohydrate (C 6 H 8 O 7 ·H 2 O FW=210.14) 52.5g citric acid monohydrate (M = 210.14g / mol) was weighed into a suitable flask. 500ml milli-Q water was added and the solution was stirred until the material was completely dissolved.

[0052] Solution B: 0.25 M trisodium citrate, dihydrate (C 6 H 5 O 7 Na 3 ·2H 2 O FW=294.12) 18.4 g trisodium citrate, dihydrate (M = 294.12 g / mol) was weighed into a suitable flask. 500 ml milli-Q water was added and the solution was stirred until the material was completely dissolved. Approximately 415 ml of Solution A and approximately 85 ml of Solution B were mixed to obtain approximately 500 ml of 0.25 M citrate buffer pH 3.0. If necessary, the pH was adjusted to 3.0±0.05 using 1 M HCl solution or 1 M NaOH. The buffer was filtered using a 0.45 μm HAWP mixed cellulose ester filter (Merck, Darmstadt, Germany) and degassed in an ultrasonic bath for 20 min before use.

[0053] Example 1.2: Protein sample preparation The proteins tested are mAbA and mAbB. mAbA is a monoclonal antibody (approximately 152 kDa) with a pI of approximately 7.01 to 8.58. It is a TFF-purified mAb formulated in 10 mM citrate buffer pH 5.5, 0.1 M NaCl, and 0.1 M glycine. The solution has a concentration of 16 mg / mL. mAbB is a monoclonal antibody (approximately 145 kDa) with a pI of approximately 7.6-8.3. It is a TFF-purified mAb formulated in 50 mM sodium acetate, pH 5.0. The solution has a concentration of 80 mg / mL.

[0054] Table 1: Sample preparation for in vitro excipient screening [Table 1]

[0055] Example 1.3: Stress conditions Stress conditions were initiated by diluting the mAb samples 1:20 (final concentrations of 0.8 mg / ml for mAbA and 4 mg / ml for mAbB) in the selected buffer conditions (0.1 M citrate buffer pH 2.8). The initial samples were measured directly by SE-HPLC after dilution with the selected buffer. Aggregation kinetics were monitored by repeating measurements every 30 minutes for 2 hours. All samples were also measured by nano-differential scanning fluorimetry (nanoDSF) for melting point (Tm) analysis. These stock solutions were used to prepare various excipient formulations (see Table 1 for pipetting schemes for buffer conditions).

[0056] Example 1.4: Size Exclusion Chromatography (SEC) Conditions Column: TSKgel SuperSW3000 System: Agilent 1290 UHPLC Flow rate: 0.35ml / min Eluent: 0.025M NaH2PO4 * H2O / 0.025M Na2HPO4 / 0.4M NaClO4 * H2O / pH6.3 Samples: mAbA and mAbB under low pH screening conditions

[0057] The results regarding the protein stabilizing effect of the excipients sorbitol and arginine HCl are shown in Figure 1. A protein stabilizing effect was observed for the addition of 0.5 M sorbitol; a destabilizing effect was observed for the addition of 0.5 M arginine HCl.

[0058] Example 1.5: NanoDSF conditions NanoDSF is a modified differential scanning fluorimetry method that utilizes intrinsic tryptophan or tyrosine fluorescence to determine protein stability. Protein stability can be addressed through thermal unfolding experiments. Protein thermal stability is typically described by its "melting temperature" or "Tm," the temperature at which 50% of the protein population is unfolded and corresponds to the midpoint of the folded-to-unfolded transition.

[0059] The analysis was performed using a Prometheus NT 48 (NanoTemper Technologies GmbH, Munich, Germany) with a sample volume of 10 μl, a heating rate of 1°C / min, and a temperature ramp starting from 20°C and continuing up to 95°C. The results regarding the protein stabilizing effect of the excipients sorbitol and arginine HCl are shown in Figure 2. A protein stabilizing effect was observed for the addition of 0.5 M sorbitol; a destabilizing effect was observed for the addition of 0.5 M arginine HCl.

[0060] As shown in Figures 4 and 5, based on the screening results using selected excipients (sorbitol, mannitol, sucrose, trehalose, PEG4000, and arginine HCl), neutral excipients such as polyols (e.g., mannitol, sorbitol) and disaccharides (e.g., sucrose, trehalose) and PEG4000 were found to effectively stabilize mAbs in solution during low pH treatment.

[0061] Example 2: Preparation of buffer and excipient solutions for Protein A chromatography All buffers and excipients were filtered using a 0.45 μm HAWP mixed cellulose ester filter (Merck, Darmstadt, Germany) and degassed in an ultrasonic bath for 20 min before use. For all Protein A chromatography runs, the following buffers were prepared and used:

[0062] Table 2: Buffer A1 for Protein A chromatography pH 5.50 [Table 2]

[0063] Table 3: Buffer A2 for Protein A chromatography pH 7.00 [Table 3]

[0064] Table 4: Buffer B for Protein A chromatography pH 2.75 [Table 4] The following excipients were selected based on their ability to protect antibodies from aggregation:

[0065] Table 5: Applied concentrations, manufacturers and quality standards of applied excipients [Table 5]

[0066] Example 2.1: Preparation of 0.5 M sucrose in citrate buffer pH 5.5 171.1 g sucrose (M = 342.29 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 5.5 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 5.5 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric graduated flask, filled to the mark with 0.1 M Na-citrate buffer pH 5.5, and mixed thoroughly.

[0067] Example 2.2: Preparation of 0.5 M sucrose in citrate buffer pH 2.75 171.1 g sucrose (M = 342.29 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 2.75 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 2.75 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 2.75, and mixed thoroughly.

[0068] Example 2.3: Preparation of 0.5 M trehalose in citrate buffer pH 5.5 171.1 g trehalose (M = 342.29 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 5.5 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 5.5 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 5.5 and mixed thoroughly.

[0069] Example 2.4: Preparation of 0.5 M trehalose in citrate buffer pH 2.75 171.1 g trehalose (M = 342.29 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 2.75 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 2.75 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 2.75, and mixed thoroughly.

[0070] Example 2.5: Preparation of 0.5 M mannitol in citrate buffer pH 5.5 91.09 g mannitol (M = 182.17 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 5.5 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 5.5 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 5.5, and mixed thoroughly.

[0071] Example 2.6: Preparation of 0.5 M mannitol in citrate buffer pH 2.75 91.09 g mannitol (M = 182.17 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 2.75 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 2.75 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 2.75, and mixed thoroughly.

[0072] Example 2.7: Preparation of 0.5 M sorbitol in citrate buffer pH 5.5 91.09 g sorbitol (M = 182.17 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 5.5 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 5.5 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 5.5, and mixed thoroughly.

[0073] Example 2.8: Preparation of 0.5 M sorbitol in citrate buffer pH 2.75 91.09 g sorbitol (M = 182.17 g / mol) was weighed into a suitable flask. Approximately 800 ml 0.1 M Na-citrate buffer pH 2.75 was added and the solution was stirred until the material was completely dissolved. The pH was adjusted to 2.75 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000.0 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 2.75, and mixed thoroughly.

[0074] Example 2.9: Preparation of 5% (w / v) PEG 4000 in citrate buffer pH 5.5 50 g of PEG4000 (M = 3500-4500 g / mol) was weighed into a suitable flask. Approximately 800 ml of 0.1 M Na-citrate buffer pH 5.5 was added, and the solution was stirred until the substance was completely dissolved. The pH was adjusted to 5.5 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 5.5, and mixed thoroughly.

[0075] Example 2.10: Preparation of 5% (w / v) PEG 4000 in citrate buffer pH 2.75 50 g of PEG4000 (M = 3500-4500 g / mol) was weighed into a suitable flask. Approximately 800 ml of 0.1 M Na-citrate buffer pH 2.75 was added, and the solution was stirred until the material was completely dissolved. The pH was adjusted to 2.75 ± 0.05 using 1 M HCl. The solution was then transferred to a 1000 ml volumetric flask, filled to the mark with 0.1 M Na-citrate buffer pH 2.75, and mixed thoroughly.

[0076] Example 3: Protein A Chromatography Example 3.1: Protein A Chromatography Resin The Eshmuno® substrate is a rigid, hydrophilic, polyvinyl ether-based polymer onto which is immobilized the pentameric form of the C domain of Staphylococcus aureus protein A, recombinantly produced in E. coli. Eshmuno® A was manufactured by Merck (Darmstadt, Germany) and the column was packed by Repligen GmbH (Ravensburg, Germany).

[0077] Table 6: Column parameters of applied Eshmuno® A resin [Table 6]

[0078] The ProSep® Ultra Plus resin has a controlled pore glass matrix and, as a ligand, recombinant native Protein A. ProSep® Ultra Plus was manufactured by Merck (Darmstadt, Germany), and the column was packed by Repligen GmbH (Ravensburg, Germany).

[0079] Table 7: Column parameters of the applied ProSep® Ultra Plus resin [Table 7]

[0080] MabSelect TM SuRe TMThe resin has an agarose matrix. Immobilized to it via a thioether is a recombinantly produced (E. coli) tetramer of an engineered Protein A domain with a C-terminal cysteine. The resin was produced by GE Healthcare (Uppsala, Sweden) and the column was packed by Repligen GmbH (Ravensburg, Germany).

[0081] Table 8: Applied MabSelect TM SuRe TM Resin column parameters [Table 8]

[0082] Example 3.2: Protein sample preparation The first model protein was the monoclonal antibody mAbA (approximately 152 kDa) with a pI of approximately 7.01-8.58. It was used as clarified cell culture harvest filtered using a VacuCap® 90PF filter unit with a 0.8 / 0.2 μm Supor® membrane (Pall Corporation, NY, USA). The solution had a concentration of 0.943 mg / mL, a pH of 7.0, and a conductivity of 12 mS / cm.

[0083] The second model protein was a monoclonal antibody, mAbB (approximately 145 kDa), with a pI of approximately 7.6-8.3, produced by Merck (Darmstadt, Germany). This was used as clarified cell culture harvest filtered using a VacuCap® 90PF filter unit with a 0.8 / 0.2 μm Supor® membrane (Pall Corporation, NY, USA). The solution had a concentration of 1.45 mg / mL, a pH of 7.0, and a conductivity of 12.87 mS / cm.

[0084] Example 3.3: Protein A Chromatography Protein A chromatography was performed using the following method parameters: Table 9: Method parameters for Protein A chromatography [Table 9] Elution was performed with a defined gradient gradient by applying a 30 CV linear gradient from pH 5.5 to pH 2.75.

[0085] Example 4: Size Exclusion Chromatography Following elution, the mAb-containing elution product pool from Protein A chromatography was subjected to viral inactivation by incubation at low pH for 1 hour at room temperature, followed by neutralization to the desired pH in the range of 4.0 to 8.0. The low pH treatment, which mimics the viral inactivation process step, was initiated by adjusting the pH of the elution product pool to pH 2.8 ± 0.05 by titration with 1 M HCl. The effect of low pH incubation on various model proteins, with or without added stabilizing excipients, was subsequently analyzed by high-performance size-exclusion chromatography (HP-SEC).

[0086] HP-SEC analysis conditions: [Table 10]

[0087] Figures 5 and 6 show the results of the HP-SEC analysis. The high content of monomeric mAb in samples containing selected neutral excipients (sorbitol, mannitol, sucrose, trehalose, and PEG4000) indicates that these excipients have an overall positive impact on protein stability during Protein A chromatography and the subsequent low-pH viral inactivation step.

[0088] Example 5: Preparation of buffer and excipient solutions for viral inactivation experiments Example 5.1: Preparation of 1M citric acid solution 21.01 g citric acid monohydrate (M = 210.14 g / mol) was weighed into a suitable flask. 100 ml milli-Q water was added and the solution was stirred until the material was completely dissolved. The solution was filtered using a 0.2 μm filter.

[0089] Example 5.2: Preparation of 0.1 M citrate buffer, pH 3.5 Solution A: 0.1 M citric acid monohydrate (C 6 H 8 O 7 ·H 2 O FW=210.14) 21.01 g citric acid monohydrate (M=210.14 g / mol) was weighed into a suitable flask. 1000 ml milli-Q water was added and the solution was stirred until the material was completely dissolved. Solution B: 0.1 M trisodium citrate, dihydrate (C 6 H 5 O 7 Na 3 ·2H 2 O FW=294.12) 29.41 g trisodium citrate, dihydrate (M = 294.12 g / mol) was weighed into a suitable flask. 1000 ml milli-Q water was added and the solution was stirred until the material was completely dissolved. Approximately 700 ml of Solution A and approximately 300 ml of Solution B were mixed to obtain approximately 1000 ml of 0.1 M citrate buffer pH 3.5. The pH of the solution was adjusted to 3.5±0.05 using 1 M citric acid solution or 1 M NaOH, if necessary.

[0090] Example 5.3: Preparation of 0.5 M sorbitol in 0.1 M citrate buffer pH 3.5 9.1 g sorbitol (M = 182.17 g / mol) was weighed into an appropriate flask. Approximately 80 ml 0.1 M citrate buffer pH 3.5 was added, and the solution was stirred until the substance was completely dissolved. The pH was adjusted to 3.5 ± 0.05 using 1 M citric acid solution or 1 M NaOH. The solution was then transferred to a 100.0 ml volumetric flask, filled to the mark with 0.1 M citrate buffer pH 3.5, and mixed thoroughly. The solution was filtered using a 0.2 μm filter.

[0091] Example 5.4: Preparation of 0.5 M mannitol in 0.1 M citrate buffer pH 3.5 9.1 g mannitol (M = 182.17 g / mol) was weighed into a suitable flask. Approximately 80 ml 0.1 M citrate buffer pH 3.5 was added, and the solution was stirred until the substance was completely dissolved. The pH was adjusted to 3.5 ± 0.05 using 1 M citric acid solution or 1 M NaOH. The solution was then transferred to a 100.0 ml volumetric flask, filled to the mark with 0.1 M citrate buffer pH 3.5, and mixed thoroughly. The solution was filtered using a 0.2 μm filter.

[0092] Example 5.5: Preparation of 0.5 M sucrose in 0.1 M citrate buffer pH 3.5 17.1 g sucrose (M = 342.29 g / mol) was weighed into a suitable flask. Approximately 80 ml 0.1 M citrate buffer pH 3.5 was added, and the solution was stirred until the material was completely dissolved. The pH was adjusted to 3.5 ± 0.05 using 1 M citric acid solution or 1 M NaOH. The solution was then transferred to a 100.0 ml volumetric flask, filled to the mark with 0.1 M citrate buffer pH 3.5, and mixed thoroughly. The solution was filtered using a 0.2 μm filter.

[0093] Example 5.6: Preparation of 0.5 M trehalose in 0.1 M citrate buffer pH 3.5 17.1 g trehalose (M = 342.29 g / mol) was weighed into a suitable flask. Approximately 80 ml 0.1 M citrate buffer pH 3.5 was added, and the solution was stirred until the substance was completely dissolved. The pH was adjusted to 3.5 ± 0.05 using 1 M citric acid solution or 1 M NaOH. The solution was then transferred to a 100.0 ml volumetric flask, filled to the mark with 0.1 M citrate buffer pH 3.5, and mixed thoroughly. The solution was filtered using a 0.2 μm filter.

[0094] Example 5.7: Preparation of 0.5 M PEG 4000 in 0.1 M citrate buffer pH 3.5 5 g of PEG4000 (M = 3500-4500 g / mol) was weighed into an appropriate flask. Approximately 80 ml of 0.1 M citrate buffer pH 3.5 was added, and the solution was stirred until the substance was completely dissolved. The pH was adjusted to 3.5 ± 0.05 using 1 M citric acid solution or 1 M NaOH. The solution was then transferred to a 100.0 ml volumetric flask, filled to the mark with 0.1 M citrate buffer pH 3.5, and mixed thoroughly. The solution was filtered using a 0.2 μm filter.

[0095] Example 6: Efficacy of excipients for viral reduction during low pH inactivation placement Xenotropic murine leukemia virus (MLV) was used as a model virus for viral reduction experiments. MLV represents a non-defective gammaretrovirus. The inclusion of MLV is mandatory for CHO cell line-derived biological products and monoclonal antibody production.

[0096] Table 10: Applied model viruses [Table 11] The model protein applied was mAbB as described in Example 1.2.

[0097] Table 11: Applied model proteins [Table 12] All assays were performed using TCID 50 This was done using the infectivity method.

[0098] Starting material preparation Prior to spiking, the material was thawed in a 37°C ± 1°C water bath with gentle inversion, and the container was removed from the water bath as soon as the ice had completely melted. For low pH load samples, samples were received at 130 mg / ml and diluted to a final concentration of 10 mg / ml using either buffer alone (0.1 M citrate buffer pH 3.5 according to Example 5.2) or excipients in citrate buffer (according to Examples 4.3-4.7).

[0099] To adjust to the desired protein concentration, a 1 in 13 dilution had to be prepared, e.g., 1 part low pH load added to 12 parts buffer or excipient in citrate buffer. The sample was mixed throughout the run and low pH dwell. Once the sample temperature reached 20° C.±0.5° C., the pH was adjusted to pH 3.6 using 1 M citric acid and / or 1 M Tris.

[0100] For the spike, 50 ml of the pH-adjusted sample was spiked. The remainder was adjusted to pH 6.0-8.0 with 1 M Tris, and a 5 ml sample was dispensed for spiking. This sample served as the time zero neutralization control and was spiked with 5% (v / v) MLV. A virus spike (5% v / v) was added to the neutralized control sample. The sample was then divided equally to create a neutralized load sample and a load indwell sample. The pH of the neutralized load sample was confirmed, and the sample was placed on ice prior to titration. The load indwell sample was kept at the same temperature as the bulk sample.

[0101] Approximately 5% (v / v) of the virus spike was added to the pH-adjusted 50 ml sample. Five minutes after the spike (T=5 min), the sample was removed and immediately neutralized with 1 M Tris. The low pH treatment was carried out at pH 3.6-3.64 (target pH 3.6) at 20°C ± 0.5°C. The pH was monitored throughout the incubation period and adjusted to the target pH (pH 3.6) as needed.

[0102] Samples were removed at T=15 min and T=30 min. The pH of the samples was immediately adjusted to pH 6.0-pH 8.0 with 1 M Tris. After 60 min at pH 3.6, the remainder was adjusted to pH 6.0-pH 8.0 with 1 M Tris.

[0103] Process Steps A chart recorder was used to monitor the temperature throughout each experiment. Recording intervals were 1 minute. All process steps are shown in Figure 7 and described below, and all volumes referenced in Figure 7 are approximate volumes.

[0104] Following addition of the virus spike, the material was mixed thoroughly prior to any further manipulation and collection of any samples. After collection, all samples were thoroughly mixed and immediately neutralized with 1 M Tris to a pH range of 6.00–8.00, as needed. The volume required for the assay was placed on ice and filtered through a 0.45 μm filter immediately prior to titration. 0.45 μm filtered and unfiltered positive controls were inoculated.

[0105] Figures 8 and 9 show the results of virus reduction experiments during low pH inactivation dwell in the presence of selected neutral excipients (sorbitol, mannitol, sucrose, trehalose, and PEG4000) compared to excipient-free samples. Based on the viral reduction factor and robustness assessment, unit operations can be classified as effective, ineffective, or moderately effective (FDA Q5A, 1998). An "effective" step provides a reduction factor of at least 4 log10 and is not affected by small perturbations in process variables. An "ineffective" step provides a reduction factor of 1 log10 or less, and a "moderately effective" step falls between these two extremes (EMD Millipore, 2013).

[0106] The utilization of the selected excipients still allowed for an effective virus reduction step (reduction factor of >4 log10) in all cases, with or without the selected excipients, clearly demonstrating that the selected excipients do not adversely affect the virus inactivation process step.

Claims

1. A method for purifying a monoclonal antibody from a cell culture sample, comprising a Protein A affinity chromatography step and a viral inactivation step, wherein the cell culture sample contains a monoclonal antibody, a virus, and impurities, and wherein the affinity chromatography step comprises: a) loading a Protein A affinity chromatography column with a cell culture sample, thereby binding the monoclonal antibody to the Protein A affinity chromatography column; b) eluting the monoclonal antibody from the Protein A affinity chromatography column by contacting the column with an elution buffer having a pH<6 and comprising an excipient, wherein the excipient is selected from the group consisting of disaccharides, polyols, and poly(ethylene glycol) polymers, provided that when the excipient is poly(ethylene glycol) polymer, the elution buffer does not contain added NaCl; c) collecting one or more fractions containing the monoclonal antibodies obtained from step (b); d) forming an elution product pool from the fractions obtained from step (c); and wherein the viral inactivation step is e) incubating the elution product pool with the excipients of step (b) at a pH of 2-3.64; The method comprising:

2. 10. The method of claim 1, wherein the poly(ethylene glycol) polymer has an average molecular weight of 1,000 g / mol to 10,000 g / mol.

3. 3. The method of claim 1, wherein the excipient is selected from the group consisting of sucrose, trehalose, sorbitol, mannitol, and PEG 4000.

4. 4. The method of claim 3, wherein the elution buffer has an excipient concentration of 2% to 15% by weight when the excipient is PEG 4000, and an excipient concentration in the solution ranging from 1 mM to 1.5 M when the excipient is sucrose, trehalose, sorbitol, or mannitol.

5. 5. The method of claim 3, wherein the elution buffer has an excipient concentration of 5% to 10% by weight when the excipient is PEG 4000, and an excipient concentration in the range of 5 mM to 500 mM in solution when the excipient is sucrose, trehalose, sorbitol, or mannitol.

6. The method according to any one of claims 1 to 5, wherein the elution buffer is a citrate buffer.

7. The method according to any one of claims 1 to 6, wherein the elution buffer has a pH of 2.5 to 5.

5.

8. 8. The method of any one of claims 1 to 7, wherein the elution step (b) comprises contacting the Protein A affinity chromatography column with an elution buffer using an elution buffer gradient from pH 5.5 to pH 2.

75.

9. 9. The method of any one of claims 1 to 8, wherein prior to incubation step (e), the pH of the elution product pool is adjusted to a pH in the range of pH 2 to pH 3.

64.

10. 10. The method of any one of claims 1 to 9, wherein the incubation step (e) is carried out at a pH between 2.5 and 3.

64.

11. The method of any one of claims 1 to 10, wherein the incubation step (e) is carried out at room temperature.

Images